(HSTM) HealthStream - Ratings and Ratios
Platform, Credentialing, Scheduling, Assessment
HSTM EPS (Earnings per Share)
HSTM Revenue
Description: HSTM HealthStream
HealthStream Inc. (NASDAQ:HSTM) is a healthcare technology company that offers a suite of Software-as-a-Service (SaaS) applications designed to support the complex needs of healthcare organizations across the United States. The companys product portfolio includes hStream, a technology platform that enables seamless integration of various healthcare applications; CredentialStream, a comprehensive provider lifecycle management solution that streamlines recruiting, credentialing, privileging, and enrollment processes; ShiftWizard, a scheduling and workforce management tool; and Competency Suite, an AI/ML-driven clinical competency development system that helps healthcare organizations assess and develop the skills of their workforce.
The companys solutions cater to the diverse needs of healthcare organizations, including private, not-for-profit, and government entities, as well as pharmaceutical and medical device companies, and nursing schools and students. By leveraging HealthStreams SaaS-based applications, healthcare organizations can improve their clinical development, talent management, training, education, assessment, competency management, safety and compliance, and scheduling capabilities. With a strong presence in the healthcare technology sector, HealthStream has established itself as a trusted partner for healthcare organizations seeking to enhance their operational efficiency and quality of care.
Analyzing the
Given the current market conditions and the companys fundamentals, a potential trading strategy could involve monitoring HSTMs price action around the 52W Low, looking for signs of a bullish reversal, such as a break above the SMA20 or a significant increase in trading volume. Additionally, investors may want to keep a close eye on the companys upcoming earnings reports and guidance, as these can provide important insights into the companys growth prospects and potential catalysts for the stock price.
HSTM Stock Overview
| Market Cap in USD | 769m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2000-04-05 |
HSTM Stock Ratings
| Growth Rating | 8.95% |
| Fundamental | 66.3% |
| Dividend Rating | 37.9% |
| Return 12m vs S&P 500 | -16.3% |
| Analyst Rating | 3.80 of 5 |
HSTM Dividends
| Dividend Yield 12m | 0.42% |
| Yield on Cost 5y | 0.59% |
| Annual Growth 5y | 5.83% |
| Payout Consistency | 38.1% |
| Payout Ratio | 18.1% |
HSTM Growth Ratios
| Growth Correlation 3m | -52.3% |
| Growth Correlation 12m | -43.1% |
| Growth Correlation 5y | 59.4% |
| CAGR 5y | 6.54% |
| CAGR/Max DD 5y | 0.17 |
| Sharpe Ratio 12m | 0.36 |
| Alpha | -13.21 |
| Beta | 0.543 |
| Volatility | 24.86% |
| Current Volume | 171.1k |
| Average Volume 20d | 188.3k |
| Stop Loss | 27.2 (-3.1%) |
| Signal | -0.75 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (20.3m TTM) > 0 and > 6% of Revenue (6% = 17.7m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 1.44pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.83% (prev 9.55%; Δ 0.28pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 62.4m > Net Income 20.3m (YES >=105%, WARN >=100%) |
| Net Debt (-36.2m) to EBITDA (65.4m) ratio: -0.55 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (30.5m) change vs 12m ago -0.02% (target <= -2.0% for YES) |
| Gross Margin 65.64% (prev 66.36%; Δ -0.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 59.06% (prev 57.10%; Δ 1.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 3.91
| (A) 0.06 = (Total Current Assets 144.4m - Total Current Liabilities 115.4m) / Total Assets 500.1m |
| (B) 0.23 = Retained Earnings (Balance) 116.8m / Total Assets 500.1m |
| (C) 0.05 = EBIT TTM 23.2m / Avg Total Assets 499.9m |
| (D) 2.34 = Book Value of Equity 350.6m / Total Liabilities 149.6m |
| Total Rating: 3.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.26
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 5.47% = 2.74 |
| 3. FCF Margin 15.35% = 3.84 |
| 4. Debt/Equity 0.43 = 2.41 |
| 5. Debt/Ebitda 2.29 = -0.56 |
| 6. ROIC - WACC -1.49% = -1.86 |
| 7. RoE 5.70% = 0.47 |
| 8. Rev. Trend 97.16% = 4.86 |
| 9. Rev. CAGR 3.72% = 0.47 |
| 10. EPS Trend 74.89% = 1.87 |
| 11. EPS CAGR 15.23% = 1.52 |
What is the price of HSTM shares?
Over the past week, the price has changed by +4.27%, over one month by +4.94%, over three months by +0.19% and over the past year by -1.48%.
Is HealthStream a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HSTM is around 26.46 USD . This means that HSTM is currently overvalued and has a potential downside of -5.77%.
Is HSTM a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HSTM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34 | 21.1% |
| Analysts Target Price | 34.5 | 22.9% |
| ValueRay Target Price | 29 | 3.4% |
Last update: 2025-08-15 15:19
HSTM Fundamental Data Overview
CCE Cash And Equivalents = 90.6m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 38.7164
P/E Forward = 39.0625
P/S = 2.6046
P/B = 2.1933
P/EG = 3.2506
Beta = 0.431
Revenue TTM = 295.2m USD
EBIT TTM = 23.2m USD
EBITDA TTM = 65.4m USD
Long Term Debt = 34.2m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 115.4m USD (from totalCurrentLiabilities, last quarter)
Debt = 149.6m USD (Calculated: Short Term 115.4m + Long Term 34.2m)
Net Debt = -36.2m USD (from netDebt column, last quarter)
Enterprise Value = 827.9m USD (768.9m + Debt 149.6m - CCE 90.6m)
Interest Coverage Ratio = unknown (Ebit TTM 23.2m / Interest Expense TTM 0.0)
FCF Yield = 5.47% (FCF TTM 45.3m / Enterprise Value 827.9m)
FCF Margin = 15.35% (FCF TTM 45.3m / Revenue TTM 295.2m)
Net Margin = 6.89% (Net Income TTM 20.3m / Revenue TTM 295.2m)
Gross Margin = 65.64% ((Revenue TTM 295.2m - Cost of Revenue TTM 101.4m) / Revenue TTM)
Tobins Q-Ratio = 2.36 (Enterprise Value 827.9m / Book Value Of Equity 350.6m)
Interest Expense / Debt = 0.17% (Interest Expense 250.0k / Debt 149.6m)
Taxrate = 19.34% (from yearly Income Tax Expense: 4.80m / 24.8m)
NOPAT = 18.7m (EBIT 23.2m * (1 - 19.34%))
Current Ratio = 1.25 (Total Current Assets 144.4m / Total Current Liabilities 115.4m)
Debt / Equity = 0.43 (Debt 149.6m / last Quarter total Stockholder Equity 350.6m)
Debt / EBITDA = 2.29 (Net Debt -36.2m / EBITDA 65.4m)
Debt / FCF = 3.30 (Debt 149.6m / FCF TTM 45.3m)
Total Stockholder Equity = 357.1m (last 4 quarters mean)
RoA = 4.07% (Net Income 20.3m, Total Assets 500.1m )
RoE = 5.70% (Net Income TTM 20.3m / Total Stockholder Equity 357.1m)
RoCE = 5.94% (Ebit 23.2m / (Equity 357.1m + L.T.Debt 34.2m))
RoIC = 5.25% (NOPAT 18.7m / Invested Capital 357.1m)
WACC = 6.74% (E(768.9m)/V(918.5m) * Re(8.02%)) + (D(149.6m)/V(918.5m) * Rd(0.17%) * (1-Tc(0.19)))
Shares Correlation 5-Years: -70.0 | Cagr: -0.80%
Discount Rate = 8.02% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈42.4m ; Y1≈52.3m ; Y5≈89.3m
Fair Price DCF = 51.24 (DCF Value 1.52b / Shares Outstanding 29.6m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 97.16 | Revenue CAGR: 3.72%
Rev Growth-of-Growth: -0.67
EPS Correlation: 74.89 | EPS CAGR: 15.23%
EPS Growth-of-Growth: -19.33
Additional Sources for HSTM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle